[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Takuma T, Okada K, Uchida Y, Yamagata A, Sawae Y: Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia. J Intern Med; 2002 Aug;252(2):173-7
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia.
  • We herein describe three cases of subacute respiratory failure that occurred during the recovery phase of neutropenia following induction chemotherapy for acute leukaemia with IPA.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Aspergillosis / complications. Leukemia / drug therapy. Lung Diseases, Fungal / complications. Neutropenia / complications. Respiratory Insufficiency / microbiology

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12190893.001).
  • [ISSN] 0954-6820
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Eichler AF, Batchelor TT, Henson JW: Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro Oncol; 2007 Jul;9(3):373-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.
  • Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications.
  • Subacute MTX neurotoxicity is manifest by abrupt onset of focal cerebral dysfunction occurring days to weeks after MTX administration, usually in children.
  • We describe the neuroimaging features of an adult patient with primary CNS lymphoma who presented with transient aphasia and right hemiparesis 12 days after receiving intravenous high-dose MTX (8 g/m2) chemotherapy.
  • The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity.
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Humans. Lymphoma / drug therapy. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2003 Jan 28;60(2):326-8 [12552054.001]
  • [Cites] Pediatr Radiol. 2006 Mar;36(3):205-12 [16369780.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):101 [12764767.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Oct;24(9):1887-90 [14561622.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Neurology. 2004 Mar 9;62(5):832-3 [15007149.001]
  • [Cites] Ann Neurol. 1978 May;3(5):441-4 [310278.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 1:89-98 [6948611.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):159-61 [6602269.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1356-60 [3875390.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1845-50 [3465876.001]
  • [Cites] AJR Am J Roentgenol. 1989 Dec;153(6):1283-8 [2816647.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 Aug;14(3):276-8 [1380777.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):246-54 [9440749.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):239-42 [9858151.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] J Neurooncol. 2005 May;73(1):47-9 [15933817.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Aug;26(7):1686-9 [16091514.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):153-7 [16132495.001]
  • [Cites] Chemotherapy. 2003 May;49(1-2):92-104 [12714818.001]
  • (PMID = 17522329.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1907407
  •  go-up   go-down


3. Marsh JC, Gielda BT, Herskovic AM, Abrams RA: Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches. J Oncol; 2010;2010:198208
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whole brain radiotherapy (WBRT) for the palliation of metastases, or as prophylaxis to prevent intracranial metastases, can be associated with subacute and late decline in memory and other cognitive functions.
  • Moreover, these changes are often increased in both frequency and severity when cranial irradiation is combined with the use of systemic or intrathecal chemotherapy.
  • Approaches to preventing or reducing this toxicity include the use of stereotactic radiosurgery (SRS) instead of WBRT; dose reduction for PCI; exclusion of the limbic circuit, hippocampal formation, and/or neural stem cell regions of the brain during radiotherapy; avoidance of intrathecal and/or systemic chemotherapy during radiotherapy; the use of high-dose, systemic chemotherapy in lieu of WBRT.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14686-91 [11121069.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2302-8 [11304784.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):15-22 [11443604.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):231-6 [11773174.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):237-46 [11773175.001]
  • [Cites] J Neurosci Res. 2002 Sep 15;69(6):745-9 [12205667.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Curr Opin Neurol. 2003 Apr;16(2):129-34 [12644738.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):249-77 [12690652.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):734-40 [12695214.001]
  • [Cites] Neuroscience. 2003;119(3):635-42 [12809684.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2726-31 [12860951.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4021-7 [12874001.001]
  • [Cites] Pediatr Neurosurg. 2003 Nov;39(5):264-9 [14512691.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Lung Cancer. 2003 Dec;42 Suppl 1:S53-6 [14611915.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):157-65 [14701778.001]
  • [Cites] Neurology. 2004 Feb 10;62(3):451-6 [14872029.001]
  • [Cites] Ann Neurol. 2004 Mar;55(3):381-9 [14991816.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Radiat Res. 2004 Jul;162(1):39-47 [15222778.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2701-7 [15226337.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Exp Neurol. 2004 Aug;188(2):316-30 [15246832.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):466-75 [15274059.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Support Oncol. 2004 Mar-Apr;2(2):127-32; discussion 133-5, 138-40 [15328816.001]
  • [Cites] J Neurosci Res. 2004 Oct 1;78(1):16-28 [15372495.001]
  • [Cites] Neurologist. 2004 Nov;10(6):293-310 [15518596.001]
  • [Cites] Br J Radiol. 2005 Feb;78(926):150-2 [15681328.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):173-9 [15803013.001]
  • [Cites] Hippocampus. 2005;15(6):722-38 [15986407.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Aug;3(8):625-6 [16167048.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):201-5 [16193393.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):44-52 [16206733.001]
  • [Cites] Arch Neurol. 2005 Oct;62(10):1595-600 [16216945.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S33-44; discusssion S1-4 [16237287.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S66-77; discusssion S1-4 [16237291.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):662-6 [16280677.001]
  • [Cites] Hippocampus. 2006;16(3):296-304 [16411241.001]
  • [Cites] Hippocampus. 2006;16(3):329-43 [16435309.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1295-304 [16525185.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2483-91 [16757720.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):335-45 [16942676.001]
  • [Cites] J Neurosci Res. 2006 Nov 15;84(7):1425-37 [17006899.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4570-4 [17008697.001]
  • [Cites] Curr Treat Options Oncol. 2006 Nov;7(6):479-89 [17032560.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Neurosurgery. 2007 Feb;60(2):277-83; discussion 283-4 [17290178.001]
  • [Cites] Neuropediatrics. 2006 Dec;37(6):364-6 [17357039.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1260-6 [17401015.001]
  • [Cites] N Engl J Med. 2007 Aug 16;357(7):664-72 [17699816.001]
  • [Cites] Ann Neurol. 2007 Nov;62(5):515-20 [17786983.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):324S-339S [17873178.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4987-92 [17971598.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Feb;29(2):379-83 [17974610.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2007 Oct;6(5):326-35 [18045161.001]
  • [Cites] Horm Res. 2008;69(2):65-74 [18059086.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):840-6 [18342502.001]
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1142-54 [18569638.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):78-84 [19047288.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12):647-54 [19107345.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12):655-62 [19107346.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1127-30 [19194463.001]
  • [Cites] Oncology. 2009;76(3):220-8 [19218826.001]
  • [Cites] Semin Radiat Oncol. 2009 Apr;19(2):122-32 [19249650.001]
  • [Cites] Prog Neurol Surg. 2009;23:76-85 [19329862.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):467-74 [19386548.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1037-44 [19801201.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Neurol Med Chir (Tokyo). 1991 Jun;31(6):336-41 [1724298.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Neurology. 1989 Jun;39(6):789-96 [2725874.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):183-90 [7707405.001]
  • [Cites] Stroke. 1995 Jan;26(1):131-6 [7839383.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):556-64 [8636771.001]
  • [Cites] Acta Oncol. 1996;35(6):659-63 [8938210.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):525-32 [9090416.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(11):1752-8 [9470828.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3563-9 [9817276.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2700-9 [10561344.001]
  • [Cites] Am J Clin Oncol. 1999 Dec;22(6):573-9 [10597741.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):191-7 [10931100.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3004-11 [10944134.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Am J Clin Oncol. 2000 Oct;23(5):487-90 [11039509.001]
  • (PMID = 20671962.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2910483
  •  go-up   go-down


Advertisement
4. Iarussi D, Indolfi P, Galderisi M, Bossone E: Cardiac toxicity after anthracycline chemotherapy in childhood. Herz; 2000 Nov;25(7):676-88
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac toxicity after anthracycline chemotherapy in childhood.
  • Overt heart failure occurs in 4.5% to 7% of patients treated with anthracyclines and the incidence of cardiac function abnormalities increases with the time.
  • This cardiotoxicity can be divided, on the base of when it started, into acute, subacute and progressive late, chronic form.
  • Various invasive and non-invasive methods have been used to measure the extent of cardiac damage done.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathies / chemically induced. Heart Failure / chemically induced. Leukemia / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Child. Dose-Response Relationship, Drug. Female. Humans. Male. Risk Factors. Sex Factors


5. Reddy LH, Marque PE, Dubernet C, Mouelhi SL, Desmaële D, Couvreur P: Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther; 2008 May;325(2):484-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
  • This study investigates 1) the anticancer efficacy of a new squalenoyl prodrug of gemcitabine (SQgem) in nanoassembly form compared with gemcitabine at equitoxic doses and 2) the subacute and acute preclinical toxicity of these compounds.
  • Using this spaced dosing schedule, SQgem nanoassemblies exhibited impressive anticancer activity in mice bearing L1210 leukemia because this treatment led to 75% long-term survivors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Leukemia / drug therapy. Nanostructures / therapeutic use. Squalene / chemistry. Squalene / therapeutic use
  • [MeSH-minor] Animals. Cytarabine / therapeutic use. Drug Evaluation, Preclinical. Mice. Mice, Inbred DBA. Nanomedicine. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258784.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 7QWM220FJH / Squalene; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Lu CH, Yao M, Liu HM, Chen YF: MR findings of intrathecal chemotherapy-related myelopathy in two cases: mimicker of subacute combined degeneration. J Neuroimaging; 2007 Apr;17(2):184-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR findings of intrathecal chemotherapy-related myelopathy in two cases: mimicker of subacute combined degeneration.
  • We report the findings of spinal magnetic resonance imaging (MRI) in 2 patients who had undergone intrathecal chemotherapy and presented with the subacute onset of ascending numbness and weakness.
  • The imaging findings are similar to those seen in subacute combined degeneration (SCD), but the serum vitamin B(12) levels were normal in these 2 cases.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Spinal Cord Diseases / chemically induced. Spinal Cord Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymphoma, B-Cell / drug therapy. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Subacute Combined Degeneration / diagnosis

  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441843.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Igata A: Clinical studies on rising and re-rising neurological diseases in Japan--a personal contribution. Proc Jpn Acad Ser B Phys Biol Sci; 2010;86(4):366-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) SMON (subacute myelo-optico-neuropathy).
  • Through the chemical analysis of the green urine, characteristic of this disease, it was found that this disease was caused by intoxication of the administered clioquinol, an anti-diarrheal drug.
  • 3) In 1972, we noticed a group of sporadic paraparesis in Kagoshima, which was 20 years later confirmed to be induced by human T lymphotropic virus type-I (HTLV-I).
  • It gave a strong impact that the causative virus of adult T cell leukemia (ATL) can induce entirely different diseases, in terms of both the clinical course and the pathological features.
  • [MeSH-minor] Beriberi / epidemiology. Beriberi / etiology. Beriberi / therapy. Humans. Japan / epidemiology. Optic Nerve Diseases / chemically induced. Optic Nerve Diseases / epidemiology. Optic Nerve Diseases / therapy. Paraparesis, Tropical Spastic / complications. Paraparesis, Tropical Spastic / epidemiology. Paraparesis, Tropical Spastic / etiology. Paraparesis, Tropical Spastic / transmission

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1973 Aug 17;47(1):13-20 [4270607.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Clin Chim Acta. 1980 Dec 8;108(2):159-68 [7449142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Ann Neurol. 1987 Feb;21(2):117-22 [2881513.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1981 Dec;44(7):1444-57 [6979154.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 Jul 12;2(8498):104-5 [2873363.001]
  • [Cites] Lancet. 1987 Jan 10;1(8524):106 [2879161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • (PMID = 20431261.001).
  • [ISSN] 1349-2896
  • [Journal-full-title] Proceedings of the Japan Academy. Series B, Physical and biological sciences
  • [ISO-abbreviation] Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC3417800
  •  go-up   go-down


8. Marshall R, Gupta ND, Palacios E, Neitzschman HR: Progressive paresthesia and weakness after intrathecal chemotherapy. J La State Med Soc; 2008 Mar-Apr;160(2):92-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive paresthesia and weakness after intrathecal chemotherapy.
  • A 53-year-old woman was diagnosed with acute lymphoblastic leukemia (ALL) confirmed by bone marrow biopsy to be pre-B ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Muscle Weakness / etiology. Paresthesia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Subacute Combined Degeneration / chemically induced
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Injections, Spinal. Magnetic Resonance Imaging. Middle Aged. Thoracic Vertebrae. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681351.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


9. Pascual AM, Coret F, Casanova B, Láinez MJ: Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci; 2008 Apr 15;267(1-2):158-61
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient paraparesis has been reported with intrathecal chemotherapy agents and the most common cause is an incomplete inflammatory myelopathy.
  • We report a case of a 30-year-old man diagnosed with acute lymphoblastic leukaemia who developed subacute anterior lumbosacral polyradiculopathy following intrathecal methotrexate, an unusual complication of intrathecal chemotherapy in adults.
  • Differential diagnosis included toxic and neoplastic polyradiculopathy, and axonal variant of acute inflammatory demyelinating polyradiculoneuropathy.
  • The authors review possible pathogenic mechanisms and propose several therapeutic and preventive options.
  • [MeSH-major] Lumbosacral Plexus / drug effects. Methotrexate / adverse effects. Paraparesis / chemically induced. Polyradiculopathy / chemically induced. Spinal Nerve Roots / drug effects
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Interactions / physiology. Fatal Outcome. Humans. Hydrocortisone / administration & dosage. Injections, Spinal / adverse effects. Leg / innervation. Leg / physiopathology. Male. Motor Neurons / pathology. Muscle, Skeletal / innervation. Muscle, Skeletal / physiopathology. Neural Conduction / physiology. Paralysis / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Respiratory Tract Infections. Sepsis. Urinary Bladder, Neurogenic / chemically induced

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949753.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, Steinmetz A, Stein J, Goshen Y, Yaniv I: Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol; 2000 Sep;15(9):573-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
  • These effects can be categorized as immediate, acute to subacute, or chronic neurologic syndromes.
  • The acute to subacute syndrome occurs frequently in acute lymphoblastic leukemia treatment protocols, generally manifesting with focal neurologic signs and changes seen on magnetic resonance imaging and single photon emission computed tomography.
  • While in some patients the neurotoxicity is transient and benign and allows for continuation of chemotherapy, in others it can be quite severe and debilitating, leading to permanent neurologic deficits.
  • The need to modify the treatment protocols when neurotoxicity appears is not fully established.
  • It is also unknown whether the use of sufficient amounts of leucovorin can overcome the toxic effects of the drug.
  • [MeSH-minor] Adolescent. Adult. Central Nervous System / diagnostic imaging. Central Nervous System / pathology. Child. Child, Preschool. Electroencephalography. Female. Humans. Leucovorin / therapeutic use. Magnetic Resonance Imaging. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tomography, Emission-Computed, Single-Photon

  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11019787.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Hengel CL, Russell PA, Gould PA, Kaye DM: Subacute anthracycline cardiotoxicity. Heart Lung Circ; 2006 Feb;15(1):59-61
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacute anthracycline cardiotoxicity.
  • We describe the case of 25-year-old man, with acute myeloid leukaemia, who presented with a myopericarditis syndrome 17 days post consolidation chemotherapy with high dose cytarabine and idarubicin.
  • In conjunction, pulsed tissue Doppler analysis revealed low early diastolic annular velocities, consistent with diastolic dysfunction.
  • Endomyocardial biopsy showed severe interstitial myocardial oedema in the absence of a cellular infiltrate or myofibre damage.
  • We believe this is the first case of subacute anthracycline toxicity described with the pathological findings of isolated myocardial oedema.
  • [MeSH-minor] Adult. Cytarabine / adverse effects. Humans. Idarubicin / adverse effects. Leukemia, Erythroblastic, Acute / drug therapy. Male

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473794.001).
  • [ISSN] 1443-9506
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


12. Haykin M, Gorman M, van Hoff J, Fulbright R, Baehring J: Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol; 2006 Jan;76(2):153-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.
  • OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.
  • Diffusion-weighted MRI (DWI) may help to distinguish between ischemic stroke and chemotherapy-related leukoencephalopathy.
  • Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX.
  • DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX.
  • [MeSH-minor] Adolescent. Diffusion Magnetic Resonance Imaging. Edema / chemically induced. Edema / pathology. Female. Humans. Leukemia, B-Cell / complications. Leukemia, B-Cell / drug therapy. Leukemia, B-Cell / pathology. Magnetic Resonance Imaging. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):319-27 [12078863.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2800-6 [9256122.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Chemotherapy. 2003 May;49(1-2):92-104 [12714818.001]
  • [Cites] J Investig Med. 1996 Dec;44(9):522-30 [9035605.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):239-42 [9858151.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Sep;20(8):1491-9 [10512236.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):159-61 [6602269.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Oct;24(9):1887-90 [14561622.001]
  • [Cites] Acta Haematol. 2004;111(4):230-2 [15153718.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1592-7 [13679276.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] Neurology. 1991 Nov;41(11):1847-8 [1944923.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):326-8 [12552054.001]
  • [Cites] J Comput Assist Tomogr. 2000 Sep-Oct;24(5):735-7 [11045695.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 1:89-98 [6948611.001]
  • [Cites] Radiology. 2000 Nov;217(2):331-45 [11058626.001]
  • [Cites] Neurology. 2004 Mar 9;62(5):832-3 [15007149.001]
  • [Cites] Eur J Cancer. 1991;27(2):219-20 [1827295.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):393-9 [12736767.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] Eur Neurol. 2004;51(2):98-103 [14752216.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):48-50 [12426687.001]
  • (PMID = 16132495.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Suzuki S, Uozumi K, Maeda M, Yamasuji Y, Hashimoto S, Komorizono Y, Owatari S, Tokunaga M, Haraguchi K, Arima N: Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. Int J Hematol; 2006 Jun;83(5):429-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection.
  • A liver allograft recipient developed acute-type adult T-cell leukemia (ATL) during tacrolimus treatment, 2 years after undergoing transplantation for subacute fulminant hepatitis.
  • Both donor and recipient were asymptomatic carriers of human T-cell lymphotropic virus type I (HTLV-I), but the ATL cells originated from the recipient.
  • Tacrolimus treatment was discontinued, and combination chemotherapy was administered.
  • The patient achieved complete remission, but the transplanted liver was acutely and chronically rejected.
  • The patient did not respond to rescue therapy with tacrolimus, prednisolone, and mycophenolate mofetil and died of hepatic failure.
  • Liver biopsies showed CD4+ ATL cell infiltration at the onset of ATL but not at the terminal stage.
  • [MeSH-major] Hepatitis / complications. Leukemia-Lymphoma, Adult T-Cell / etiology. Liver Failure, Acute / complications. Liver Transplantation. Living Donors
  • [MeSH-minor] Fatal Outcome. Graft Rejection / drug therapy. Graft Rejection / etiology. Graft Rejection / virology. Humans. Male. Middle Aged. Transplantation, Homologous


14. Haykin ME, Gorman M, van Hoff J, Fulbright RK, Baehring JM: Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol; 2006 Jan;76(2):153-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.
  • OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.
  • Diffusion-weighted MRI (DWI) may help to distinguish between ischemic stroke and chemotherapy-related leukoencephalopathy.
  • Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX.
  • DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX.
  • [MeSH-minor] Adolescent. Diffusion Magnetic Resonance Imaging. Edema / chemically induced. Edema / pathology. Female. Humans. Leukemia, B-Cell / drug therapy. Leukemia, B-Cell / pathology. Leukemia, Lymphoid / complications. Magnetic Resonance Imaging. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):319-27 [12078863.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2800-6 [9256122.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Chemotherapy. 2003 May;49(1-2):92-104 [12714818.001]
  • [Cites] J Investig Med. 1996 Dec;44(9):522-30 [9035605.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):239-42 [9858151.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Sep;20(8):1491-9 [10512236.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):159-61 [6602269.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Oct;24(9):1887-90 [14561622.001]
  • [Cites] Acta Haematol. 2004;111(4):230-2 [15153718.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1592-7 [13679276.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] Neurology. 1991 Nov;41(11):1847-8 [1944923.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):326-8 [12552054.001]
  • [Cites] J Comput Assist Tomogr. 2000 Sep-Oct;24(5):735-7 [11045695.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 1:89-98 [6948611.001]
  • [Cites] Radiology. 2000 Nov;217(2):331-45 [11058626.001]
  • [Cites] Neurology. 2004 Mar 9;62(5):832-3 [15007149.001]
  • [Cites] Eur J Cancer. 1991;27(2):219-20 [1827295.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):393-9 [12736767.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] Eur Neurol. 2004;51(2):98-103 [14752216.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):48-50 [12426687.001]
  • (PMID = 16411025.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Schanz J, Weiss B, Henrich D, Bohrer MH, Uppenkamp M: [30 year-old patient with multiple pelvic lesions and fecal incontinence]. Internist (Berl); 2009 Sep;50(9):1155, 1157-60
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Multiple Raumforderungen bei einem 30-Jährigen mit Stuhlinkontinenz.
  • In a 30 year-old patient with subacute loss of bowel control and perianal anesthesia radiologic examination showed multiple bone lesions.
  • The results of a bone marrow aspiration showed acute myeloid leukemia M2 with translocation t(8,21) associated with granulocytic sarcoma.
  • The patient was treated with high dose chemotherapy and had a complete remission after autologous stem cell transplantation.
  • [MeSH-major] Fecal Incontinence / prevention & control. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / surgery. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(1):84-9 [14745436.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):466-75 [9053467.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1283-7 [9179903.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):969 [9521985.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1643-8 [9269784.001]
  • [Cites] Int J Hematol. 2005 Oct;82(3):210-4 [16207593.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):690-7 [8478662.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):767-73 [15735660.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):862-6 [16740041.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • [Cites] Clin Neurol Neurosurg. 1991;93(4):341-4 [1665771.001]
  • (PMID = 19585093.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Umehara F, Hagiwara T, Yoshimura M, Higashi K, Arimura K: Enlarged, multifocal upper limb neuropathy with HTLV-I associated myelopathy in a patient with chronic adult T-cell leukemia. J Neurol Sci; 2008 Mar 15;266(1-2):167-70
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enlarged, multifocal upper limb neuropathy with HTLV-I associated myelopathy in a patient with chronic adult T-cell leukemia.
  • The authors herein describe a case of multifocal peripheral neuropathy with HTLV-I-associated myelopathy (HAM) in a patient with chronic adult T-cell leukemia (ATL).
  • The clinical features included subacute progressive sensory-motor neuropathy in the bilateral upper limbs, and bilateral pyramidal tract involvement with bladder dysfunction.
  • An MRI with (67)gadolinium enhancement revealed enlargement of the affected peripheral nerves. (8)FDG positron emission tomography (PET) disclosed increased uptake in the affected nerves, suggesting neurolymphomatosis or inflammation.
  • Chemotherapy for ATL resulted in marked improvement of motor functions in the upper limbs.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / complications. Paraparesis, Tropical Spastic / complications. Peripheral Nervous System Diseases / etiology. Peripheral Nervous System Diseases / pathology. Upper Extremity / pathology
  • [MeSH-minor] Blood Cell Count. Contrast Media. Female. Fluorodeoxyglucose F18. Gadolinium. Humans. Magnetic Resonance Imaging. Middle Aged. Neural Conduction / physiology. Neurologic Examination. Peripheral Nerves / pathology. Peripheral Nerves / physiopathology. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096188.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


17. Tan HK, Lim JS, Tan CK, Ng HS, Chow P, Lui HF, Wong GC, Tan PH, Raghuram J, Ng HN, Choong LH, Wong KS, Woo KT: MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report. Liver Int; 2003;23 Suppl 3:52-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report.
  • The postoperative course following second surgery was complicated by severe methicillin-resistant Staphylococcus aureus (MRSA) sepsis, mild azotaemia and subacute cholestatic liver failure.
  • Case 2 was a female patient with advanced acute lymphoblastic leukaemia (ALL) with post bone marrow transplantation (BMT) acute haemolytic-uraemic syndrome (HUS) secondary to cyclosporin A (Cy A), cytomegalovirus (CMV) infection, severe nosocomial pneumonia, acute renal failure (ARF) treated with continuous haemofiltration and acute veno-occlusive disease resulting in Budd-Chiari syndrome.
  • Case 3 was a male patient with advanced, refractory Hodgkin's disease previously treated with multiple courses of chemotherapy.
  • ALF developed secondary to acute viral hepatitis B flare.
  • RESULTS: Mean MARS intradialytic systemic pressures were as follows: systolic pressure range was 95 +/- 17 to 128 +/- 17 mmHg and diastolic pressure range was 51 +/- 5 to 67 +/- 7 mmHg.
  • Ultrafiltration (UF) was 633 +/- 622 mL over mean treatment duration of 6.3 +/- 0.9 h with a total heparin dose of 1583 +/- 817 IU.
  • MARS had a significant de-uraemization effect (pre- and post-MARS serum creatinine and urea: P=0.046 and 0.028, respectively) but did not significantly attenuate blood lactate, ammonia or total bilirubin levels.
  • Although MARS had a significant de-uraemization effect, this appeared to be limited by the duration of MARS operation.
  • This would affect the optimal duration of MARS therapy.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Failure, Acute / therapy. Liver Neoplasms / therapy. Renal Dialysis. Sorption Detoxification
  • [MeSH-minor] Adolescent. Adult. Critical Illness. Fatal Outcome. Female. Hemolytic-Uremic Syndrome / etiology. Hemolytic-Uremic Syndrome / therapy. Hodgkin Disease / complications. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950962.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Lichtman MA, Rowe JM: The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol; 2004 Apr;31(2):185-97
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of the major clonal myeloid diseases, clonal cytopenias, acute, subacute (oligoblastic), and chronic myelogenous leukemia, polycythemia vera, thrombocythemia, and idiopathic myelofibrosis increases in a log-linear manner from young adulthood through advanced age.
  • In older patients, diseases requiring cytotoxic treatment are more difficult and less successful to manage because comorbid conditions and poor performance status are more prevalent, decreasing the tolerance to therapy and increasing the frequency of side effects.
  • This age effect is highlighted by the dramatically less favorable outcome in older than younger patients with acute myeloid leukemia with similar "favorable" cytogenetic changes.
  • In addition, in acute and subacute myeloid leukemia in older patients, the disease is intrinsically more resistant to therapy.
  • Overexpression of drug resistance genes and unfavorable genetic mutations are more prevalent in older patients and provide evidence that acute myeloid leukemia is often qualitatively different in these patients.
  • Although improved drug schedules have led to significant improvements in event-free survival in younger patients, these improvements have been far less evident in older patients.
  • New approaches, especially the development of drugs aimed at new targets, will be required to obtain a high frequency of long-term remissions in older patients.
  • Agents that reverse inherent cellular drug resistance, farnesyltransferase inhibitors, BCL-2 inhibitors, and FLT3 inhibitors are early examples of such approaches.
  • [MeSH-major] Leukemia, Myeloid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15112149.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


19. Abahji TN, Kastenbauer S, Scherwat J, Schmieder S, Anders HJ: [A 68-year-old patient with atrial flutter/fibrillation, inadequate anticoagulation, subacute amaurosis, normal ESR, and lymphadenopathy]. Internist (Berl); 2008 Jul;49(7):873-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 68-year-old patient with atrial flutter/fibrillation, inadequate anticoagulation, subacute amaurosis, normal ESR, and lymphadenopathy].
  • [Transliterated title] 68-jähriger Patient mit Vorhofflattern/Vorhofflimmern, inadäquater Antikoagulation, subakuter Amaurosis, normaler BSG und Lymphadenopathie.
  • We present a rare manifestation of chronic lymphatic leukemia with progressive bilateral visual loss and the typical fundoscopic picture of anterior ischemic optic nerve neuropathy (AION).
  • Clinical symptoms were due to meningeal metastases and tumor cell infiltration of the optic nerve.
  • [MeSH-major] Anticoagulants / administration & dosage. Atrial Fibrillation / drug therapy. Atrial Fibrillation / etiology. Atrial Flutter / drug therapy. Atrial Flutter / etiology. Blindness / etiology. Lymphatic Diseases / complications

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Neurol. 2000;20(1):97-110 [10874780.001]
  • [Cites] Am J Ophthalmol. 1996 Oct;122(4):535-41 [8862051.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Brain. 1975 Dec;98(4):689-708 [1218373.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):317-28 [12208242.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):524-7 [9167611.001]
  • [Cites] Retina. 2001;21(4):348-51 [11508881.001]
  • [Cites] Br J Ophthalmol. 1974 Dec;58(12):955-63 [4376415.001]
  • [Cites] JAMA. 1995 Feb 22;273(8):625-32 [7844872.001]
  • [Cites] Ophthalmologica. 1999;213(2):76-96 [9885384.001]
  • [Cites] J Neuroophthalmol. 2003 Jun;23(2):157-63 [12782932.001]
  • (PMID = 18431559.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


20. Turtureanu-Hanganu E: Emergency care: the tumor lysis syndrome. Rev Med Chir Soc Med Nat Iasi; 2002 Oct-Dec;106(4):705-11
Hazardous Substances Data Bank. Allopurinol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Tumor Lysis Syndrome (TLS) is a constellation of metabolic disturbances due to the rapid tumoral cell destruction, either spontaneous or induced by cytoreduction therapy, which manifests as an acute, subacute or chronic renal insufficiency.
  • The therapy consists in management of hydro-electrolytic and metabolic disturbances, treatment of hyperuricemia (Allopurinol and a new therapeutical agent, Uricase), hemodialysis.
  • If promptly supported during the TLS, a number of these patients have an excellent probability of long-term remission.
  • [MeSH-major] Tumor Lysis Syndrome / therapy
  • [MeSH-minor] Adult. Allopurinol / therapeutic use. Antimetabolites / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Emergencies. Humans. Hyperuricemia / etiology. Leukemia / drug therapy. Lymphoma / drug therapy. Renal Dialysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14974215.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antimetabolites; 63CZ7GJN5I / Allopurinol
  •  go-up   go-down


21. Léonard S, Hulin C, Anxionnat R, Grignon Y, Taillandier L, Vespignani H: [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia]. Rev Neurol (Paris); 2002 Nov;158(11):1121-3
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
  • [Transliterated title] Leucoencéphalopathie multifocale progressive après traitement par fludarabine dans une leucémie lymphoïde chronique.
  • A 74-year- man was hospitalized for subacute aphasia and right hemiparesis.
  • He had had chronic lymphoid leukemia for 11 years and had been treated 5 months earlier with 3 courses of fludarabine.
  • The diagnosis of PML was confirmed.
  • The causality of fludarabine treatment is discussed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukoencephalopathy, Progressive Multifocal / chemically induced. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12451348.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


22. Cid J, Revilla M, Cervera A, Cervantes F, Muñoz E, Ferrer I, Montserrat E: Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol; 2000 Jul;79(7):392-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disorder of the central nervous system usually affecting immunocompromised individuals and is due to infection of the oligodendrocytes by the JC virus.
  • A case of PML in a chronic lymphocytic leukemia (CLL) patient treated with fludarabine is reported, representing the second such instance in which the diagnosis of the neurological disorder was established by brain biopsy.
  • A 61-year-old man with a 14-year history of B-cell type CLL, for which he had received chlorambucil therapy 10 years earlier, developed progressive paresis of both left extremities at 7 months of receiving low doses of oral fludarabine, when his CD4 count has decreased to 0.08 x 10(9)/l.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukoencephalopathy, Progressive Multifocal / chemically induced. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


23. Viallard JF, Lazaro E, Lafon ME, Pellegrin JL: Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1659-62
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • Despite attempts with various drugs, PML has generally remained unresponsive to treatment.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • Despite attempts with various drugs, PML has generally remained unresponsive to treatment.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • [MeSH-major] Cytosine / analogs & derivatives. Immunoblastic Lymphadenopathy / complications. Leukoencephalopathy, Progressive Multifocal / drug therapy. Lymphoma, T-Cell / complications. Organophosphonates / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334909.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


24. Pöhlmann C, Hochauf K, Röllig C, Schetelig J, Wunderlich O, Bandt D, Ehninger G, Jacobs E, Rohayem J: Chlorpromazine combined with cidofovir for treatment of a patient suffering from progressive multifocal leukoencephalopathy. Intervirology; 2007;50(6):412-7
Hazardous Substances Data Bank. Chlorpromazine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorpromazine combined with cidofovir for treatment of a patient suffering from progressive multifocal leukoencephalopathy.
  • We report on a stem cell-transplanted patient with B cell chronic lymphatic leukemia who presented with a subacute onset of focal neurological deficits, gait abnormalities, emotional lability and dementia.
  • Progressive multifocal leukoencephalopathy was diagnosed by magnetic resonance imaging (MRI) of the brain and detection of JC virus genome in the cerebrospinal fluid.
  • A follow-up MRI of the brain 2 weeks after initiation of the antiviral therapy displayed progress of the demyelination, and the patient died 3 months after onset of the neurological symptoms.
  • This report highlights the need for the development of novel and potent strategies for treatment of progressive multifocal leukoencephalopathy.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antiviral Agents / administration & dosage. Brain / drug effects. Chlorpromazine / administration & dosage. Cytosine / analogs & derivatives. JC Virus. Leukoencephalopathy, Progressive Multifocal / drug therapy. Organophosphonates / administration & dosage
  • [MeSH-minor] DNA, Viral / cerebrospinal fluid. Drug Therapy, Combination. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18182774.001).
  • [ISSN] 1423-0100
  • [Journal-full-title] Intervirology
  • [ISO-abbreviation] Intervirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


25. Korinthenberg R, Schneider A, Niemeyer C: Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia. J Child Neurol; 2002 Jun;17(6):409-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.
  • Acute, subacute, and chronic neurologic complications have been reported in children treated with high-dose methotrexate for various malignant diseases.
  • It was the aim of this study to monitor central nervous system treatment with high-dose methotrexate in children with acute lymphoblastic leukemia by serial electroencephalographic (EEG) examinations.
  • Electroencephalographic examinations with quantitative computed analysis were performed in 21 children before and on the third day after each of four high-dose methotrexate infusions with leucovorin rescue according to protocol M of trial ALL-BFM 90 of the German Society for Pediatric Haematology and Oncology.
  • Six patients with a medium risk of relapse also received L-asparaginase.
  • Only two children with delayed serum methotrexate clearance showed reversible diffuse EEG slowing of a slight to moderate degree.
  • In the group with additional L-asparaginase treatment, slight transient EEG slowing also occurred.
  • Our findings indicate that in patients with a normal methotrexate clearance during central nervous system treatment with high-dose methotrexate according to trial BFM-ALL 90, usually no subacute or cumulative EEG changes have to be expected.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Brain / drug effects. Central Nervous System Neoplasms / prevention & control. Electroencephalography / drug effects. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Child. Child, Preschool. Female. Humans. Infant. Injections, Intravenous. Injections, Spinal. Leucovorin / administration & dosage. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174959.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.5.1.1 / Asparaginase; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Arkenau HT, Gordon C, Murphy F, Cunningham D: Paraneoplastic syndrome: subacute cerebellar degeneration in Hodgkin's disease. Leuk Lymphoma; 2007 Apr;48(4):819-22
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic syndrome: subacute cerebellar degeneration in Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / diagnosis. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cerebellar Diseases / drug therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Spinocerebellar Degenerations / diagnosis. Spinocerebellar Degenerations / pathology. Treatment Outcome


27. Strunk T, Gottschalk S, Goepel W, Bucsky P, Schultz C: Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Med Pediatr Oncol; 2003 Jan;40(1):48-50
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
  • [MeSH-minor] Adolescent. Heterozygote. Humans. Injections, Spinal. Male. Methylenetetrahydrofolate Reductase (NADPH2). Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12426687.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.- / Oxidoreductases Acting on CH-NH Group Donors; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement